Scarica l'app Stockscreener
272.11
0.99%
2.68
Dopo l'orario di chiusura:
272.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$269.43
Aprire:
$276.97
Volume 24 ore:
3.09M
Relative Volume:
0.99
Capitalizzazione di mercato:
$145.97B
Reddito:
$32.53B
Utile/perdita netta:
$4.23B
Rapporto P/E:
34.84
EPS:
7.81
Flusso di cassa netto:
$6.28B
1 W Prestazione:
+3.77%
1M Prestazione:
+2.32%
6M Prestazione:
-18.94%
1 anno Prestazione:
-10.51%
Intervallo 1D:
$269.78
$276.97
Intervallo di 1 settimana:
$261.28
$276.97
Portata 52W:
$253.30
$346.85
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Confronta AMGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
272.11 | 145.97B | 32.53B | 4.23B | 6.28B | 7.81 |
|
LLY
Lilly Eli Co
|
725.72 | 689.73B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
78.69 | 349.44B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
147.03 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
171.56 | 303.17B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
97.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Cell and Gene Therapy Market Set to Witness Significant Growth by 2025-2032: Pfizer, Inc., Sanofi S.A., Amgen, - EIN News
Amgen: Likely To Be Rangebound (Rating Downgrade) - Seeking Alpha
Willner & Heller LLC Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer - Yahoo Finance Australia
Amgen Inc. (AMGN): A Bull Case Theory - Insider Monkey
Annex Advisory Services LLC Has $4.11 Million Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
FDA approves Amgen’s combo therapy for colorectal cancer - Yahoo Finance
Sax Wealth Advisors LLC Makes New $252,000 Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Kelly Financial Services LLC Invests $3.78 Million in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Here’s Why Amgen Inc. (AMGN) Is Among the Highest Yielding Dividend Stocks In the Dow - Insider Monkey
HB Wealth Management LLC Buys 1,768 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Cohen Klingenstein LLC Sells 1,750 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Verity & Verity LLC Raises Stock Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Trimmed by Aaron Wealth Advisors LLC - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Stock Position Lifted by Merit Financial Group LLC - MarketBeat
Why Amgen Inc. (AMGN) Is One of the Best Cheap Stocks to Buy for 2025? - Insider Monkey
Amgen picks up key colorectal cancer okay for KRAS drug - pharmaphorum
Why Is Amgen Inc. (AMGN) Among Louis Navellier’s Top Long-term Stock Picks? - Insider Monkey
Avanza Fonder AB Makes New Investment in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Tompkins Financial Corp Buys 16,481 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Zoran Krunic, Senior Manager of Data Science at Amgen The Superposition Guy's Podcast: Workforce Development - The Quantum Insider
Boston Common Asset Management LLC Has $5.66 Million Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Householder Group Estate & Retirement Specialist LLC Has $412,000 Position in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Empirical Asset Management LLC Purchases 3,156 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Ritholtz Wealth Management Decreases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen's (NASDAQ:AMGN) Upcoming Dividend Will Be Larger Than Last Year's - Simply Wall St
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
FDA Approves Amgen Treatment For Pretreated Colorectal Cancer With Certain Mutation - Benzinga
Amgen : Advancement in Combination Biomarker Driven Therapy for Adult Patients with Chemorefractory KRAS G12C Mutated Metastatic Colorectal Cancer (mCRC) - Marketscreener.com
FDA Approves Amgen’s LUMAKRAS + Vectibix for KRAS G12C-mutated Colorectal Cancer - Contract Pharma
FDA approves Amgen's Lumakras with Vectibix for mCRC - World Pharmaceutical Frontiers
FDA Approves Amgen's Groundbreaking LUMAKRAS Combination Therapy for Colorectal Cancer Treatment - StockTitan
Looking beyond obesity, Amgen wins colorectal cancer expansion for Lumakras - PharmaLive
FDA Greenlights Amgen's New Cancer Drug Combo, Boosting Survival for KRAS G12C Patients - GuruFocus.com
Occidental Asset Management LLC Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,620 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Bennett Associates Wealth Management - MarketBeat
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer - Seeking Alpha
Carnegie Investment Counsel Grows Stock Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
JGP Wealth Management LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
1,041 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by Tallon Kerry Patrick - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Godsey & Gibb Inc. Increases Holdings in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
US FDA approves Amgen's colorectal cancer therapy - Reuters.com
Is Amgen Inc. (AMGN) Among the Best NASDAQ Dividend Stocks to Buy? - Insider Monkey
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
Flywheel Private Wealth LLC Acquires New Shares in Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc. (NASDAQ:AMGN) Shares Sold by Argent Capital Management LLC - MarketBeat
Alzheimers Drugs Market Projected To Reach USD 12.26 Bn by - GlobeNewswire
Amgen Reveals Ocrelizumab Biosimilar Ambitions - News & Insights
Wolff Wiese Magana LLC Purchases 1,644 Shares of Amgen Inc. (NASDAQ:AMGN) - MarketBeat
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.72%
0.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):